Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| hrpc prostate |
|
Urological Specialists - Chicago, Illinois - Prostate Cancer Hormone-refractory (or hormone-independent) prostate cancer (HRPC): prostate cancer that no longer requires androgens as a growth signal. Search - HisandHerHealth: Information About Sexuality, Prostate New Research Gives Insights to Prostate Problem Solving (Latest in Urology News/AUA) . All had HRPC - prostate cancer that progr. Search - HisandHerHealth: Information About Sexuality, Prostate All had HRPC - prostate cancer that progressed after hormonal therapy - and one-third had a previous SRE. Median age was 72 years, median time bet. The use of trastuzumab in the treatment of hormone refractory efficacy in treating HRPC. Prostate 60: 332â“337, 2004. # 2004 Wiley-Liss, Inc. KEY WORDS:. prostate; cancer; trastuzumab; HER-2 receptor. INTRODUCTION Expert Opinion - Expert Opinion on Investigational Drugs - 17(1 Novel therapeutic strategies in development for prostate cancer. of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). Mechanisms of the development of androgen independence in prostate transcriptionally active in HRPC prostate cancer and. can increase cell proliferation even with castrate levels of. testosterone. In addition, these results Blackwell Synergy - Prostate J, Volume 2 Issue 3 Page 116-122 ( 1996) Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): prostate specific antigen (PSA) response and antiandrogen withdrawal Secondary hormonal manipulation of prostate cancer The treatment of patients with hormone-resistant prostate. cancer (HRPC) remains a clinical challenge, although. treatment options have expanded in the last New strategies for the medical treatment of prostate cancer that cancer cells are accumulated. The actual. magnitude of this imbalance is problematic in. curing HRPC. Prostate cancer is a disease A Prognostic Score for Hormone-Refractory Prostate Cancer Previously, we have shown that serial measurements of prostate-specific antigen (PSA) in hormone-refractory prostate cancer (HRPC) can be used to calculate Prostate Cancer - Research and Markets - RSS Feed Prostate Cancer publications from researchandmarkets.com . We have Metastatic and HRPC Prostate Cancer Insight details physician opinion of cur Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer Datamonitor's Metastatic and HRPC Prostate Cancer Insight details physician opinion of currently available products and disease management practice and what PharmGKB: Literature Annotation PURPOSE: To determine the safety and efficacy of two docetaxel doublets in hormone-refractory prostate cancer (HRPC) patients and to examine the prognostic CiteULike: Docetaxel plus prednisone or mitoxantrone plus Secondary end points were pain, prostate-specific antigen (PSA) levels, keywords = {cancer, cite, fulltext, hrpc, prostate}, month = {October}, CiteULike: The management of hormone refractory prostate cancer. Death of patients from prostate cancer is directly related to the development of clones journal = {Eur Urol}, keywords = {cancer, cite, hrpc, prostate}, Hormone Refractory Prostate Cancer - hrpca.org For those men facing hormone refractory prostate cancer. This is a support group for HRPC issues only. Urologic Oncology: Seminars and Original Investigations Although docetaxel-based chemotherapy has recently shown survival benefit for advanced hormone-refractory prostate cancer (HRPC) 2 and 3, patients and Urology : Weekly Docetaxel and Epirubicin in Treatment of Advanced for the treatment of advanced hormone-refractory prostate cancer. the first-line standard of care for advanced HRPC, prostate-specific antigen (PSA) |
| hrpc prostate |
|
prostate cancer detection massage oshawa prostate prostate cancer blood test massaged his prostate |